Physicians know the limitations of chemotherapy and radiotherapy to selectively and accurately target cancer cells in meaningful doses, and the doses required frequently lead to high levels of toxicity. However, Cancer immuno-therapy is proving a promising strategy to fight cancer involving the activation and arming of the immune system against tumors. There are many different approaches among which, oncolytic virus therapy is one of the most encouraging. Psivac has developed an advanced therapeutic cancer therapy which can infect cells and specifically kill cancerous tissue. Psivac proprietary name for this oncolytic adenovirus is Ixovex-1, which is a genetically modified tumour selective Adenovirus 5 (AdV5) with an ability to replicate and kill cancer cells. This novel therapy provides improved efficacy in the specific targeting of cancer cells with increased safety over traditional products. Due to the lack of cross-resistance with other cancer therapeutics, this technology can be used in combination with existing treatment regime to enhance their activity and mitigate against treatment resistance and disease recurrence.